HT update: spotlight on estradiol/norethindrone acetate combination therapy.
Abstract: The goal ofpostmenopausal hormone therapy is to alleviate the symptoms that are associated with the loss of estrogen. Many formulations of estrogen and progestin are available, depending on the needs and circumstances of each individual woman. For postmenopausal women, the choice of whether or not to begin therapy requires knowledge of the risks and benefits of estrogen and/or progestin replacement. The purpose of this review is to describe the risks and benefits of hormonal therapy, focusing on estradiol/norethindrone acetate combination therapy.
Casey
Colleen L
CL
University of Vermont, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Burlington,VT 05401, USA. colleen.casey@vtmednet.org
Murray
Christine A
CA
D015519:Bone Density / Q000187:drug effects; D001943:Breast Neoplasms / Q000503:physiopathology / Q000517:prevention & control; D015179:Colorectal Neoplasms / Q000503:physiopathology / Q000517:prevention & control; D003280:Contraceptives, Oral, Synthetic / Q000008:administration & dosage*; D004338:Drug Combinations; D004714:Endometrial Hyperplasia / Q000517:prevention & control; D004958:Estradiol / Q000008:administration & dosage*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D005260:Female; D006801:Humans; D008568:Memory / Q000187:drug effects; D009640:Norethindrone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077563:Norethindrone Acetate; D018570:Risk Assessment; D020521:Stroke / Q000139:chemically induced / Q000453:epidemiology; D054556:Venous Thromboembolism / Q000139:chemically induced / Q000453:epidemiology
D003280:Contraceptives, Oral, Synthetic; D004338:Drug Combinations; D004958:Estradiol; D000077563:Norethindrone Acetate; D009640:Norethindrone